USD 5.7
(-7.74%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 9.7 Million USD | 511.98% |
2022 | 1.58 Million USD | 158599900.0% |
2021 | 1.00 USD | 0.0% |
2020 | - USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 18.74 Million USD | 16.57% |
2024 Q1 | 16.08 Million USD | 65.71% |
2023 Q1 | 5.34 Million USD | 236.7% |
2023 Q3 | 6.59 Million USD | -16.16% |
2023 FY | 9.7 Million USD | 511.98% |
2023 Q4 | 9.7 Million USD | 47.26% |
2023 Q2 | 7.86 Million USD | 47.21% |
2022 Q1 | - USD | -100.0% |
2022 Q3 | 1.00 USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 FY | 1.58 Million USD | 158599900.0% |
2022 Q4 | 1.58 Million USD | 158599900.0% |
2021 Q2 | - USD | 0.0% |
2021 FY | 1.00 USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 Q4 | 1.00 USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2020 Q4 | - USD | 0.0% |
2020 FY | - USD | 0.0% |
2020 Q3 | - USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
uniQure N.V. | 12.02 Million USD | 19.278% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | 49.119% |
Amicus Therapeutics, Inc. | 59.69 Million USD | 83.741% |
bluebird bio, Inc. | 22.91 Million USD | 57.651% |
Cara Therapeutics, Inc. | 2.82 Million USD | -244.062% |
Imunon, Inc. | - USD | -Infinity% |
Editas Medicine, Inc. | - USD | -Infinity% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Mettler-Toledo International Inc. | 385.86 Million USD | 97.485% |
Myriad Genetics, Inc. | 20.1 Million USD | 51.711% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | 74.658% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 87.461% |
Verastem, Inc. | - USD | -Infinity% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.883% |
Waters Corporation | 516.23 Million USD | 98.12% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.809% |
Biogen Inc. | 2.52 Billion USD | 99.616% |
Nektar Therapeutics | 16.1 Million USD | 39.718% |
Perrigo Company plc | 1.14 Billion USD | 99.149% |
Dynavax Technologies Corporation | 53.29 Million USD | 81.786% |
Illumina, Inc. | 587 Million USD | 98.347% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | 6.421% |
Heron Therapeutics, Inc. | 42.11 Million USD | 76.951% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 99.123% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | 11.748% |
Adicet Bio, Inc. | - USD | -Infinity% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.624% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 85.209% |
FibroGen, Inc. | 41.56 Million USD | 76.649% |
Agilent Technologies, Inc. | 1.03 Billion USD | 99.059% |
OPKO Health, Inc. | 65.69 Million USD | 85.226% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 89.112% |
Exelixis, Inc. | 17.32 Million USD | 43.97% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 99.621% |
Axsome Therapeutics, Inc. | 15.13 Million USD | 35.87% |
Abeona Therapeutics Inc. | -2.44 Million USD | 497.136% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 98.686% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 65.854% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 96.994% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -25.563% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 92.393% |
Blueprint Medicines Corporation | 21.22 Million USD | 54.267% |
Insmed Incorporated | 83.24 Million USD | 88.341% |
TG Therapeutics, Inc. | 39.82 Million USD | 75.627% |
Incyte Corporation | 62.97 Million USD | 84.587% |
Emergent BioSolutions Inc. | 328.9 Million USD | 97.049% |